YOLFTbeta
68

Beijing Succeeder Technology Inc

688338 · SHG · Healthcare / Medical Devices

25.50CNY-0.39 (-1.51%)

Price History

Full chart

Market Stats

Previous Close25.89
Open26.19
Day Range25.43 – 26.19
52-Week Range23.51 – 35.71
Volume851.65K
Market Cap3.37B
P/E (TTM)39.69
Forward P/E0.00
EPS0.80
Dividend Yield0.82%
Beta0.53
50-Day Avg29.48
200-Day Avg29.16

About

Beijing Succeeder Technology Inc. engages in the research, development, production, and sales of testing instruments, reagents, and consumables in the field of in vitro diagnostics for thrombosis and hemostasis in China and internationally. The company offers coagulation testers, hemorheology testers, erythrocyte sedimentation rate and hematocrit testers, platelet aggregation testers, blood rheology analyzer, diagnostic reagents, and quality control products, as well as automated equipment with supporting testing instruments. Its products are used in the prevention, screening, diagnosis, and monitoring of thrombophilia and hemorrhagic diseases, such as stroke, coronary heart disease, and venous thromboembolism. Beijing Succeeder Technology Inc. was founded in 2003 and is based in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Hai Wang
  • Employees268
  • HeadquartersNo.19 Baili Street, Beijing, China, 102600, China
  • Websitehttps://www.succeeder.com.cn

Leadership

  • Mr. Hai WangGM & Director · b. 1971
  • Mr. Guo LiFinancial Director, Accounting Supervisor & Director · b. 1977
  • Ms. Zhonghui DingDeputy GM & Director · b. 1973
  • Ms. Tong WuDirector & Deputy General Manager · b. 1984
  • Mr. Guobin LiuDeputy General Manager & Supervisor · b. 1986
  • Mr. Zhe RenDeputy General Manager & Core Technical Personnel · b. 1985
  • Mr. Jiahong ZhangBoard Secretary · b. 1973
  • Mr. Yanbin PeiDeputy General Manager · b. 1967

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue125.37M156.70M200.09M229.57M222.40M239.92M228.81M275.49M305.87M263.67M
Growth (%)-+24.99%+27.69%+14.73%-3.12%+7.88%-4.63%+20.40%+11.03%-13.80%
Cost of Revenue54.32M66.15M84.01M93.19M88.68M95.84M86.18M104.66M118.06M100.81M
Gross Profit71.05M90.55M116.08M136.38M131.02M144.08M142.64M170.83M187.81M263.67M
Gross Margin56.67%57.78%58.01%59.41%58.91%60.05%62.34%62.01%61.40%100.00%
Operating Expense37.31M53.88M50.62M54.65M46.20M35.80M24.75M35.95M57.85M160.49M
Operating Income33.73M36.67M65.46M81.72M84.81M108.28M117.88M134.88M129.96M103.18M
Operating Margin26.91%23.40%32.71%35.60%38.14%45.13%51.52%48.96%42.49%39.13%
EBITDA35.32M39.59M65.58M84.94M81.67M120.70M126.98M140.99M141.58M114.77M
EBITDA Margin28.18%25.27%32.77%37.00%36.72%50.31%55.49%51.18%46.29%43.53%
Net Income31.02M29.35M56.71M71.04M69.19M97.37M104.11M116.91M113.00M87.14M
Net Income Margin24.74%18.73%28.34%30.95%31.11%40.58%45.50%42.44%36.94%33.05%
R&D9.29M12.07M12.80M13.86M13.36M15.21M16.94M19.18M19.60M19.34M
R&D as % of Total Revenue7.41%7.70%6.39%6.04%6.01%6.34%7.40%6.96%6.41%7.34%
Interest Expense919.89K40.40K41.76K55.67K54.38K246.41K38.06K75.53K5.35K1.51K
Interest Expense % of Total Revenue0.73%0.03%0.02%0.02%0.02%0.10%0.02%0.03%0.00%0.00%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets154.76M186.32M242.94M426.69M1.40B1.48B1.61B1.71B1.75B1.77B
Total Liabilities50.87M43.02M47.28M52.00M45.31M62.88M107.44M106.01M102.46M75.86M
Total Equity103.89M143.30M195.65M374.69M1.36B1.42B1.50B1.60B1.65B1.69B
Cash91.75M107.93M158.85M323.10M1.27B1.32B1.31B1.28B1.07B779.79M
Total Debt----6.29M4.17M738.19K181.75K61.64K-
Net Debt-91.75M-107.93M-158.85M-323.10M-1.26B-1.32B-1.31B-1.28B-1.07B-

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow35.30M32.68M58.15M60.94M72.27M107.42M100.56M109.64M122.98M79.40M
Investing Cash Flow-4.50M-2.54M-3.85M-5.10M-32.29M-15.75M-119.25M-100.72M-269.82M-
Financing Cash Flow-3.31M-13.35M-4.04M105.69M906.91M-36.78M-23.76M-22.04M-67.10M-
Capital Expenditure4.50M2.54M3.85M5.10M32.29M15.75M97.25M120.23M72.42M33.68M
Free Cash Flow30.80M30.14M54.30M55.84M39.98M91.67M3.31M-10.59M50.57M45.72M
Dividends Paid3.31M19.29M4.04M960.00K12.00M32.66M20.41M21.23M27.60M34.31M
FCF to OCF87.25%92.22%93.38%91.63%55.32%85.34%3.29%-9.65%41.12%57.58%
Dividend Paid to FCF10.75%64.00%7.44%1.72%30.02%35.63%617.33%-200.55%54.57%75.04%

Earnings

Report DateSep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate-----------
EPS Actual0.140.270.180.210.240.290.170.280.290.240.25
Surprise-----------
Timing-----------

Key Statistics & Ratios

Market Cap3.37B
Enterprise Value2.15B
Trailing P/E39.69
Forward P/E0.00
Price / Sales13.10
Price / Book2.02
EPS0.80
Book Value16.40
Revenue (TTM)257.25M
Gross Profit (TTM)158.88M
EBITDA92.16M
Profit Margin32.70%
Operating Margin30.26%
Return on Equity5.01%
Return on Assets2.85%
Shares Outstanding106.14M
Shares Float46.08M
Beta0.53
Dividend Yield0.82%
Dividend Rate0.26
Payout Ratio32.50%

Dividends

20261×
0.26Jun 4, 2026
20251×
0.33Jun 12, 2025
20241×
0.26Jun 6, 2024
20231×
0.26Jul 7, 2023
20221×
0.19Jul 7, 2022
20211×
0.31Jul 7, 2021

Stock Splits

  • Jul 7, 20231.3:1